Free Trial

Craneware (LON:CRW) Receives "Buy" Rating from Shore Capital

Craneware logo with Medical background

Shore Capital reiterated their buy rating on shares of Craneware (LON:CRW - Free Report) in a research report sent to investors on Wednesday morning, Marketbeat.com reports. Shore Capital currently has a GBX 2,650 ($35.58) target price on the stock.

Separately, Berenberg Bank initiated coverage on Craneware in a research report on Wednesday. They set a "buy" rating and a GBX 2,800 ($37.60) target price for the company.

Get Our Latest Research Report on CRW

Craneware Stock Performance

Shares of Craneware stock traded down GBX 20 ($0.27) during trading hours on Wednesday, hitting GBX 2,460 ($33.03). 31,352 shares of the company's stock traded hands, compared to its average volume of 81,196. Craneware has a 12-month low of GBX 1,330 ($17.86) and a 12-month high of GBX 2,580 ($34.64). The stock has a market capitalization of £1.06 billion, a price-to-earnings ratio of 90.89 and a beta of 0.28. The company has a fifty day simple moving average of GBX 2,114.42 and a 200-day simple moving average of GBX 1,941.58. The company has a debt-to-equity ratio of 12.22, a current ratio of 0.63 and a quick ratio of 1.00.

Insider Transactions at Craneware

In other news, insider Will Whitehorn purchased 1,911 shares of Craneware stock in a transaction that occurred on Thursday, April 24th. The shares were bought at an average cost of GBX 1,584 ($21.27) per share, with a total value of £30,270.24 ($40,647.56). 19.28% of the stock is currently owned by corporate insiders.

About Craneware

(Get Free Report)

The Craneware Group, the market leader in automated value cycle solutions, including 340B management, collaborates with U.S. healthcare providers to plan, execute, and monitor operational and financial performance so they can continue to deliver quality care to their communities. Customers choose The Craneware Group's Trisus data and applications platform as their key to navigating the journey to financially sustainable value-based care.

See Also

Should You Invest $1,000 in Craneware Right Now?

Before you consider Craneware, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Craneware wasn't on the list.

While Craneware currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines